WO2003093313A2 - Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein - Google Patents
Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein Download PDFInfo
- Publication number
- WO2003093313A2 WO2003093313A2 PCT/EP2003/004425 EP0304425W WO03093313A2 WO 2003093313 A2 WO2003093313 A2 WO 2003093313A2 EP 0304425 W EP0304425 W EP 0304425W WO 03093313 A2 WO03093313 A2 WO 03093313A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor viii
- seq
- amino acid
- lrp
- antibody
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims abstract description 174
- 230000003993 interaction Effects 0.000 title claims abstract description 60
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 title description 5
- 239000005557 antagonist Substances 0.000 title description 2
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 175
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 174
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000013060 biological fluid Substances 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 208000015294 blood coagulation disease Diseases 0.000 claims abstract description 19
- 230000007423 decrease Effects 0.000 claims abstract description 18
- 238000006731 degradation reaction Methods 0.000 claims abstract description 18
- 201000003542 Factor VIII deficiency Diseases 0.000 claims abstract description 17
- 230000015556 catabolic process Effects 0.000 claims abstract description 17
- 230000005764 inhibitory process Effects 0.000 claims abstract description 16
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims abstract 8
- 230000027455 binding Effects 0.000 claims description 71
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000027276 Von Willebrand disease Diseases 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 6
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 6
- 230000002035 prolonged effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 239000003527 fibrinolytic agent Substances 0.000 claims description 3
- 230000003480 fibrinolytic effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002537 thrombolytic effect Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 41
- 239000012634 fragment Substances 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 21
- 239000007983 Tris buffer Substances 0.000 description 20
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 20
- 108010014172 Factor V Proteins 0.000 description 18
- 239000000872 buffer Substances 0.000 description 16
- 102000002110 C2 domains Human genes 0.000 description 15
- 108050009459 C2 domains Proteins 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 229920000136 polysorbate Polymers 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 108091006905 Human Serum Albumin Proteins 0.000 description 11
- 102000008100 Human Serum Albumin Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 10
- 230000002452 interceptive effect Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 238000010494 dissociation reaction Methods 0.000 description 9
- 230000005593 dissociations Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
- 108010047303 von Willebrand Factor Proteins 0.000 description 9
- 102100036537 von Willebrand factor Human genes 0.000 description 9
- 229960001134 von willebrand factor Drugs 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- 102000057593 human F8 Human genes 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000009871 nonspecific binding Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010048049 Factor IXa Proteins 0.000 description 4
- 108010014173 Factor X Proteins 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010061932 Factor VIIIa Proteins 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002947 procoagulating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100260702 Mus musculus Tinagl1 gene Proteins 0.000 description 2
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 2
- 239000012570 Opti-MEM I medium Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 101150088826 arg1 gene Proteins 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229940105778 coagulation factor viii Drugs 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 1
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101710177612 Very low-density lipoprotein receptor Proteins 0.000 description 1
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006800 cellular catabolic process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 108010055222 clotting enzyme Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 108010012171 factor VIII receptor Proteins 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000006451 grace's insect medium Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000015316 von Willebrand disease 3 Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000034365 zymogen activation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A.
- the present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.
- Blood coagulation involves a combination of different haemostatic reaction routes which finally lead to the formation of a thrombus.
- Thrombi are clots of blood components on the surface of the walls of vessels and mainly consist of aggregated blood platelets and insoluble cross-linked fibrin. The formation of fibrin is induced by the limited proteolysis of fibrinogen by the clotting enzyme thrombin.
- This enzyme is the end-product of a coagulation cascade, which is a sequence of zymogen activations that take place at the surface of activated platelets and leucocytes and a multitude of vascular cells (see e.g. K. G. Mann et al, Blood, 1990, Vol. 76, pages 1-16; incorporated herein by reference).
- a key step in this coagulation cascade is the activation of Factor X by a complex of activated Factor IX (Factor IXa) and activated Factor VIII (Factor Villa).
- Coagulation Factor VIII is thus a key protein in the intrinsic pathway of the coagulation cascade.
- the function of FVIII is to serve as a cofactor for the enzyme FIXa and to increase the catalytic efficiency of this protease by five to six orders of magnitude (van Dieijen al. 1981. The Journal of Biological Chemistry 256: 3433-3442; incorporated herein by reference).
- the importance of FVIII is demonstrated by the severe bleeding disorder Haemophilia A, which is characterised by the absence of active FVIII (Kazazian et al. 1995. The Metabolic and Molecular Basis of Inherited Disease. In: Scriver, Beadet, Sly and Valle, Ed. New York, McGraw-Hill Inc. Ill: 3241-3267; incorporated herein by reference).
- Haemophilia A is a sex-linked bleeding disorder characterized by a deficiency in Factor VIII. The disease occurs in about 0.01% of the male population. Haemophilia A can be treated by administering Factor Vlll-containing blood plasma obtained from healthy donors. This treatment has several disadvantages, however. The supply of Factor VIII is limited and very expensive; the concentration of Factor VIII in blood is only about 100 ng/ml and the yields using current plasma fractionation methods are low. Since the source of Factor VIII is pooled donor blood, the recipient runs a high risk of acquiring various infectious diseases, including those caused by hepatitis non-A, non-B, hepatitis B or AIDS viruses which may be present in the donor blood. In addition, recipients may develop antibodies against the exogenous Factor VIII, some of which can greatly reduce its effectiveness.
- coagulation Factor VIII serves its role in the intrinsic coagulation pathway as a cofactor for activated Factor IX (FIXa) in the proteolytic activation of Factor X (for reviews, see Fay, P. J. (1999) Thromb. Haemostasis 82, 193-200; Lenting, P. J., van Mourik, J. A., and Mertens, K. (1998) Blood 92, 3983- 3996; incorporated herein by reference).
- Factor VIII is a 300-kDa glycoprotein that comprises a discrete domain structure (A1-a7-A2-a2-B-a3-A3-C1-C2) (Lenting, P. J., van Mourik, J.
- the A and C domains share 30-40% homology with the A and C domains of the structurally related protein Factor V, whereas the B domain and the short acidic regions a1, a2, and a3 are unique for FVIII (Church, W. R., Jernigan, R. L., Toole, J., Hewick, R. M., Knopf, J., Knutson, G. J., Nesheim, M. E., Mann, K. G., and Fass, D. N. (1984) Proc. Natl. Acad. Sci. U.S.A. 81 , 6934- 6937; incorporated herein by reference ).
- FVIII circulates as a metal-ion-linked heterodimer consisting of a 90- 220-kDa heavy chain (A1-a7-A2-a2-B) and an 80-kDa light chain (a3-A3-C1-C2) (Rotblat, F., O'Brien, D. P., O'Brien, F. J., Goodall, A. H., and Tuddenham, E. G. D. (1985) Biochemistry 24, 4294-4300; Kaufman, R. J., Wasly, L. C, and Dorner, A. J. (1988) J. Biol. Chem. 263, 6352-6362; incorporated herein by reference).
- the inactive protein is tightly associated with its carrier protein von Willebrand Factor (vWF) (Lollar, P., Hill-Eubanks, D. C, and Parker, C. G. (1988) J. Biol. Chem. 263, 10451-10455; incorporated herein by reference).
- vWF von Willebrand Factor
- Limited proteolysis by either thrombin or Factor Xa converts the FVIII precursor into its activated derivative (Lollar, P., Knutson, G. J., and Fass, D. N. (1985) Biochemistry 24, 8056-8064; Eaton, D., Rodriguez, H., and Vehar G. A. (1986) Biochemistry 25, 505-512; incorporated herein by reference).
- the B domain and the acidic region that borders the A3 domain are then removed from the molecule (Fay, P. J., Haidaris, P. J., and Smudzin, T. M. (1991) J. Biol. Chem. 266, 8957-8962; incorporated herein by reference), which leads to the loss of high affinity binding to vWF (Lollar, P., et al. (1988) supra).
- the resulting activated FVIII (FVIIIa) molecule consists of a heterotrimer comprising the A2-a2 domain that is non- covalently associated with the metal-ion-linked A1-a7/A3-C1-C2 moiety (Fay, P. J., et al. (1991) supra).
- the A3 domain region Glu 181 1-Lys 1818 has been identified as a FIXa interactive site (Lenting, P. J., (1996) supra).
- FVIII regions Arg 484 -Phe 509 and Lys 1804 -Lys " l 818 have also been identified as target epitopes for antibodies that may occur in hemophilia patients.
- Such antibodies inhibit FVIII activity by interfering with the complex assembly of FVIIIa and activated FIX (Haeley, J. F., Lubin, 1. M., Nakai, H., Saenko, E. L, Hoyer, L. W., Scandella, D., and Lollar, P. (1995) J. Biol.
- the half-life of Factor VIII can be prolonged by influencing the mechanism of the Factor VIII degradation (clearance), for example, by reduction of the affinity of Factor VIII for the receptors which play a role in its clearance, either directly, by modification of Factor VIII at its binding site(s) for the relevant clearance receptor(s) or indirectly, by using compounds that influence the binding between Factor VIII and its receptors. Since the cellular receptors involved in said process and the molecular sites involved in Factor Vlll-receptor interaction were not known, the production of such agents has been problematic.
- LRP Low Density Lipoprotein Receptor Protein
- non-activated FVIII interacts with the multifunctional endocytic receptor low-density lipoprotein receptor-related protein (LRP) (Lenting, P. J., Neels, J. G., van den Berg, B. M. M., Clijsters, P. P. F. M., Meijerman, D. W. E., Pannekoek, H., van Mourik, J. A., Mertens, K., and van Zonneveld, A..-J. (1999) J. Biol. Chem. 274, 23734-23739; WO 00/28021 ; Saenko, E. L, Yakhyaev, A.
- LRP multifunctional endocytic receptor low-density lipoprotein receptor-related protein
- LRP is a member of the low-density lipoprotein (LDL) receptor family that also includes LDL receptor, very low-density lipoprotein receptor, a polipoprotein E receptor 2, and megalin (for reviews see Neels J. G., Horn, I. R., van den Berg, B. M. M., Pannekoek, H., and van Zonneveld, A. -J. (1998) Fibrinolysis Proteolysis 12, 219-240; Herz, J., and Strickland, D. K. (2001) J. Clin. Invest. 108, 779-784; incorporated herein by reference).
- LDL low-density lipoprotein
- the receptor consists of an extracellular 515-kDa ⁇ -chain, which is non-covalently linked to a transmembrane 85-kDa ⁇ -chain (Herz, J., Kowal, R. C, Goldstein, J. L., and Brown, M. S. (1990) EMBO J. 9, 1769-1776; incorporated herein by reference).
- the ⁇ -chain contains four clusters of a varying number of complement-type repeats that mediate the binding of many structurally and functionally unrelated ligands (Moestrup, S.K., Hotlet, T. L., Etzerodt, M., Thogersen, H. C, Nykjaer, A., Andreasen, P. A., Rasmussen, H. H., Sottrup- Jensen, L, and Gliemann, J. (1993) J. Biol. Chem. 268, 13691-13696; Willnow, T. E., Orth, K. ( and Herz, J. (1994) J. Biol. Chem. 269, 15827-15832; Neels, J. G.
- the ⁇ -chain comprises a trans-membrane domain and a short cytoplasmatic tail which is essential for endocytosis.
- the alpha chain functions as a large ectodomain and comprises three types of repeats: epidermic growth-Factor-like domains, Tyr-Trp-Thr-Asp sequences and LDL-receptor-class A domains. These class A domains, which have been implicated in ligand binding, are present in four separate clusters which are called Cluster I (2 domains), Cluster II (8 domains), Cluster III (10 domains) and Cluster IV (11 domains).
- LRP is also expressed in cell-types like monkey kidney cells (COS) or Chinese hamster ovary cells (CHO) FitzGerald, D. J., et al., J. Cell Biol. Vol. 129, 1995, pages 1533-1541 ; incorporated herein by reference) which are those often used for the expression of mammalian proteins, including Factor VIII (Kaufman, R. J. et al., Blood, Coag. Fibrinol, vol. 8 (Suppl. 2), 1997, pages 3-14; incorporated herein by reference).
- COS monkey kidney cells
- CHO Chinese hamster ovary cells
- LRP plays a role in the clearance of a multitude of ligands, including proteases, inhibitors of the Kunitz type, protease-serpin complexes, lipases and lipoproteins which implicates that LRP plays an important role in several physiological and pathophysiological clearance processes (Narita et al., Blood, vol. 2, pages 555- 560, 1998; Orth et al., Proc. Natl. Acad. Sci., vol. 89, pages 7422-7426, 1992; Kounnas et al., J. Biol. Chem., vol. 271, page 6523-6529, 1996; incorporated herein by reference).
- LRP also binds the activated, non-enzymatic cofactor Factor Villa (Yakhyaev, A. et al., Blood, vol. 90, (Suppl. 1), 1997, 126-1). While this disclosure implicates LRP in Factor Villa regulation, there is no hint of a role for LRP in the regulation of non-activated heterodimer Factor VIII.
- FVIII light chain has been demonstrated to interact with recombinant LRP clusters II and IV, whereas no binding was observed to LRP clusters I and III (Neels, J. G., et al (1999) supra).
- WO 87/07144 describes several modifications of proteolytic cleavage sites, which comprise arginine and lysine residues, to reduce the lability of the molecule for a specific protease catalyzed cleavage, for example Factor Xa-cleavage site between Arg1?21 and Ala ⁇ 2 ⁇ .
- WO 95/18827, WO 95/18828 and WO 95/18829 describe Factor VIII derivatives with modifications in the A2 regions of the heavy chain.
- WO 97/03193 discloses a Factor VIII polypeptide analogues, wherein the modifications alter the metal binding characteristics of the molecule.
- EP 808 901 describes the construction of Factor VIII variants with at least one mutation in at least one immunodominant region of Factor VIII and use of this Factor VIII variant for the treatment of patients with Factor VIII inhibitors. These modifications do not lead to a prolonged half-life or increased stability of the Factor VIII variant in vivo or in vitro.
- WO 00/28021 describes a Factor VIII polypeptide with a Factor VIII:C activity which has modifications in the A3 and/or C1 or C2 domain of the light chain and which is characterized in that the modification influences binding affinity to low-density lipoprotein receptor protein (LRP).
- LRP low-density lipoprotein receptor protein
- a complex of two proteolytic cleavage products of Factor VIII, a 92 kDa and an 80 kDa polypeptide exhibits enhanced Factor VIII activity.
- the present invention generally concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A.
- the present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.
- FIG.1 Binding of FVIII light chain fragments to immobilized LRP.
- LRP immobilized at a CM5 sensor-chip at 16 fmol/mm 2 was incubated with: A, FVIII light chain (150 nM) (solid line) and Factor Xa-cleaved light chain (150 nM) (dotted line).
- Incubations were performed in 150 mM NaCI, 2 mM CaCI 2 , 0.005% (v/v) Tween® 20, and 20 mM Hepes (pH 7.4) at a flow rate of 20 ⁇ l/min for 2 min at 25 °C. Dissociation was initiated upon replacement of ligand solution by buffer. Response is indicated as Resonance Units (RU) and is corrected for nonspecific binding, which was less than 5% relative to LRP-coated channels.
- RU Resonance Units
- FVIII light chain (LCh) (25 nM) was incubated with immobilized LRP cluster IV (1 pmol/well) in a volume of 50 ⁇ l in 150 mM NaCI, 5 mM CaCI 2 , 1% (w/v) HSA, 0.1 % Tween® 20, and 50 mM Tris (pH 7.4) in the presence or absence of various concentrations of recombinant LRP cluster II (0-600 nM) for 2 h at 37 °C.
- FVIII light chain was quantified by incubation with peroxidase-conjugated anti-FVIII antibody CLB-CAg 12 for 15 min at 37 °C. Residual binding is expressed as the percentage of binding in the absence of competitor and is corrected for nonspecific binding (less than 5% relative to binding to LRP cluster ll-immobilized wells). Inset, serial dilutions of FVIII light chain were incubated with immobilized LRP cluster II (1 pmol/well) in a volume of 50 ⁇ l in 150 mM NaCI, 5 mM CaCI 2.
- FIG.4 Effect of scFv antibody fragments on the interaction between FVIII light chain and LRP.
- FVIII light chain (LCh) 25 nM was incubated with immobilized LRP cluster II (1 pmol/well) in a volume of 50 ⁇ l in 150 mM NaCI, 5 mM CaCI 2 , 1 % (w/v) HSA, 0.1% Tween® 20, and 50 mM Tris (pH 7.4) in the presence of various concentrations (0-100 nM) of scFv KM41 (closed circles) or scFv KM36 (open circles) for 2 h at 37 °C.
- FVIII light chain was quantified by incubation with peroxidase-conjugated anti- FVIII antibody CLB-CAg 12 for 15 min at 37 °C. Residual binding is expressed as the percentage of binding in the absence of competitor and is corrected for nonspecific binding (less than 5% relative to binding to LRP cluster li-immobilized wells). Data represent the mean ⁇ S.D. of three experiments, ⁇ , FVIII light chain (50 nM) was incubated with immobilized LRP (16 fmol/mm 2 ) as described in the legend of Fig. 1.
- Binding was assessed in the absence (c rve 7) or in the presence of increasing concentrations of scFv KM41 (20, 60, 300, 500 nM, curves 2-5, respectively). Complexes were allowed to form for 30 min before SPR analysis.
- LRP. FVIII light chain (LCh) (25 nM) was incubated with immobilized LRP cluster II (1 pmol/well) in a volume of 50 ⁇ l in 150 mM NaCI, 5 mM CaCla . 1% (w/v) HSA, 0.1% Tween® 20, and 50 mM Tris (pH 7.4) in the presence of various concentrations (0-30 nM) of scFv KM36 (open circles) or scFv KM33 (closed circles) for 2 h at 37 °C.
- FVIII Light chain was quantified by incubation with peroxidase-conjugated anti-FVIII antibody CLB-CAg 12 for 15 min at 37 °C. Residual binding is expressed as the percentage of binding in the absence of competitor and is corrected for nonspecific binding (less than 5% relative to binding to cluster-coated wells). Data represent the mean ⁇ S.D. of three experiments.
- Fig. 6 Binding of LRP cluster II to the FVIII/FV 1811-1818
- ScFv EL14 at a CM5 sensor chip (67 fmol/mm 2 ) was incubated with either the recombinant wild-type FVIII light chain or the recombinant FVIII/FV "181 1-1818 chimera till a density of 20 fmol/mm 2 , in 150 mM NaCI, 50 mM Tris (pH 7.4).
- LRP cluster II (25- 125 nM) was passed over two separate channels with immobilized FVIII/FV1 8 11-1 8 1 chimera (open circles) or intact FVIII light chain (closed circles), respectively, and one control (scFv EL14-coated) channel in 150 mM NaCI, 2 mM CaCI 2 , 0.005% (v/v) Tween® 20, and 20 mM Hepes (pH 7.4) for 2 min at a flow rate of 20 ⁇ l/min at 25 °C. Bound LRP cluster II is expressed as the amount associated after 2 min.
- Fig.7 Binding of scFv KM41 to the FVIII/FVlSH- SI 8 light chain chimera.
- ScFv EL14 at a CM5 sensor chip was incubated with either the recombinant wild-type FVIII light chain or the recombinant FVIII/FV 1 311-1 8 1 8 chimera till a density of 20 fmol/mm 2 , in 150 mM NaCI, 50 mM Tris (pH 7.4).
- ScFv KM41 40 nM was passed over two separate channels with immobilized intact FVIII light chain (I) or FVIII/FV ⁇ H' SI 8 chimera (II), respectively. Response is indicated as Resonance Units (RU) and is corrected for nonspecific binding.
- mice were injected either with human FVIII alone, human FVIII in the presence of a control scFv-fragment (KM38) and with human FVIII in the presence of a scFv-fragment (KM33) specifically interfering with the putative FVIII-LRP interaction.
- One embodiment of the invention relates to the use of a peptide comprising an amino acid sequence as defined in any of SEQ ID Nos. 1, 2, 3 or 4 as derived from Factor VIII but not having any substantial Factor VIII activity to inhibit Factor VIII interaction with LRP.
- peptide relates to a molecule that is comprised of a sequence of amino acids joined via peptide bonds.
- the peptides useful for the invention are comprised of those 20 amino acids that are commonly found in proteins (see for example, the well-known textbook “Biochemistry” by A. Lehninger, 2 nd Ed., Worth Publishers, NY, NY (1975).
- a peptide useful for the present invention can also be a derivative of a peptide comprising an amino acid sequence as defined in any of SEQ ID Nos. 1 , 2, 3 or 4, as derived from Factor VIII but not having any substantial Factor VIII activity, modified such that its amino acid sequence comprises one or more deletions, additions, substitutions and/or inversions that do not significantly alter the ability of said peptide to reduce the interaction between Factor VIII and LRP proteins.
- a peptide useful for the present invention contains one or amino acid substitution(s), it is preferable that said one or more amino acid substitution(s) are conservative amino acid substitutions.
- a substitution occurs in a non-polar hydrophobic amino acid such as alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine
- the substituted amino acid is selected from a non-polar hydrophobic amino acid such as alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
- a substitution occurs in an uncharged polar amino acid such as serine, threonine, tyrosine, asparagine, glutamine, cysteine or glycine
- the substituted amino acid is selected from an uncharged polar amino acid such as serine, threonine, tyrosine, asparagine, glutamine, cysteine or glycine.
- a substitution occurs in a positively charged (basic) amino acid such as lysine, arginine or histidine
- the substituted amino acid is selected from a positively charged (basic) amino acid such as lysine, arginine or histidine.
- the substituted amino acid is selected from a negatively charged (acidic) amino acid such as aspartic acid or glutamic acid.
- the peptide useful for the invention can be composed of D-amino acids, L-amino acids or a mixture of D- and L-amino acids.
- a peptide useful for the present invention also embraces multimeric forms of any of the peptides as defined in SEQ ID Nos. 1 , 2, 3 or 4, such as e.g. tandem or alternating repeats of one or more of these peptides.
- Peptides useful for the present invention may be produced in whole or in part by standard peptide synthesis techniques or by recombinant DNA techniques.
- One particular peptide useful for the invention comprises the amino acid sequence of SEQ ID NO:1 (Gly 8 H-Lys1 ⁇ 1 8 ).
- peptides useful for the invention comprises the amino acid sequences from SEQ ID NO:2 (Lys 804 -Lys 8 1 8 ) or SEQ ID NO:3 (Tyr S15- Ala 1834 ).
- a further peptide useful for the invention comprises the amino acid sequences Lys1S0 4 -Ala1 834 (SEQ ID NO:4).
- a peptide useful for the present invention has less that 5.0 % of the Factor VIII activity, more preferably less than 1.0 % of the Factor VIII activity, and most preferably essentially no activity, as compared to the corresponding Factor VIII activity of the naturally occurring Factor VIII molecule from which said peptide of the present invention was derived as measured in one of the above-mentioned assays for Factor VIII activity.
- the evaluation of Factor VIII activity can be carried out by means of a suitable assay, in particular with any assay that is typically performed to determine Factor VIII activity in samples, such as the one-step clot assay as described in Mikaelsson and Oswaldson, Scan. J. Hematol. Suppl. 33, 79-86, 1984, for example or a chromogenic assay such as Factor VIII IMMUNOCHROM (Baxter).
- a suitable assay in particular with any assay that is typically performed to determine Factor VIII activity in samples, such as the one-step clot assay as described in Mikaelsson and Oswaldson, Scan. J. Hematol. Suppl. 33, 79-86, 1984, for example or a chromogenic assay such as Factor VIII IMMUNOCHROM (Baxter).
- Factor VIII activity can also be performed by measuring the ability of Factor VIII to act as a cofactor for Factor IXa in the conversion of Factor X to Factor Xa, whereby a chromogenic substrate is used for Factor Xa (Coatest Factor VIII, Chomogenix, Moelndal, Sweden).
- a further embodiment of the invention relates to the use of an antibody, which specifically binds to one or more epitopes within a peptide comprising an amino acid sequence as defined in any of SEQ ID Nos. 1 , 2, 3 or 4 as derived from Factor VIII but not having any substantial Factor VIII activity, to inhibit Factor VIII interaction with LRP.
- antibody as used herein is meant to include a polyclonal or monoclonal antibody, preferably monoclonal antibody, and fragments or regions thereof as well as derivatives thereof that are capable of specifically binding to one or more epitopes within Factor VIII or a peptide useful for the present invention and interfering with the interaction between a Factor VIII molecule and a Low Density Lipoprotein Receptor-related Protein(LRP).
- LRP Low Density Lipoprotein Receptor-related Protein
- epitope as used herein is meant to refer to the whole or part of a peptide useful for the present invention that mimics the 1°, 2° and/or 3° structure of all or part of the corresponding amino acids found in Factor VIII and that is capable of being specifically recognized by an antibody that inhibits the interaction between Factor VIII and LRP.
- An epitope may comprise the peptide sequence per se, i.e. the 1 ° structure of the peptide, the peptide in various three dimensional conformations, i.e. the 2° or 3° structure of the peptide sequence and/or modifications to the amino acids of said peptides such as the addition of sugar molecules, e.g. glycosylated peptides.
- the peptides useful for practicing the present invention comprise at least two different epitopes.
- One epitope seems to be a primary amino acid sequence located within SEQ ID NO:1 (Gly1S11-Lys1 8 1 8 ).
- the other epitope may be comprised of a combination of the amino acid sequences located adjacent to the above primary epitope; i.e. the other epitope may be formed from SEQ ID NO:2 (Lys1 804 -Lys1 8 1 8 ) and/or SEQ ID NO:3 (Tyr1 8 15-Ala 1884 ).
- This epitope may also be a secondary or tertiary structure epitope and may comprise both of the amino acid sequences Lysl ⁇ O 4 - Lysl ⁇ l ⁇ and Tyr ⁇ l ⁇ -Alal 884
- Fragments of antibodies include, for example, Fab, Fab', F(ab')2, Fv and scFv fragments. These fragments can be produced from intact antibodies using methods that are well known in the art, for example by proteolytic cleavage with enzymes such as papain to produce Fab fragments, or pepsin to produce F(ab')2 fragments.
- the antibody useful for the practice of the invention is a scFv antibody fragment.
- the antibody comprises the amino acid sequence of the antibody as described in the examples as KM33 (see SEQ ID NO:20 for the amino acid sequence of the heavy chain of KM33, SEQ ID NO:22 for the amino acid sequence of the light chain of KM33 and SEQ ID NO:26 for a fusion protein comprising the light and heavy chains of KM33 joined by a peptide linker)and/or as provided by the GenBank Accession Number AF234247 (VHKM33) or the antibody as described in the examples as KM41 (see SEQ ID NO:16 for the amino acid sequence of the heavy chain of KM41, SEQ ID NO:18 for the amino acid sequence of the light chain of KM41 and SEQ ID NO:25 for a fusion protein comprising the light and heavy chains of KM41 joined by a peptide linker) and/or as provided by the GenBank Accession Number AF234258 (VLKM41
- an antibody useful for the invention is capable of inhibiting the interaction between Factor VIII and Low Density Lipoprotein Receptor-related Protein (LRP) such that this interaction is reduced by at least 20 %, more preferably at least 50 %, still more preferably at least 90 % or 95 % or more, as compared to the interaction, for example, between Factor VIII and LRP derived from a given source.
- LRP Low Density Lipoprotein Receptor-related Protein
- Factor VIII and LRP can be determined using the Surface Plasmon Resonance or solid-phase binding assays as described herein.
- LRP Low Density Lipoprotein Receptor-related Protein
- LDL low density lipoprotein
- Human LRP contains 31 class A cysteine-rich repeat (known as LDLRA) domains which are distributed in the LRP molecule in four clusters known as clusters I, II, III and IV.
- Cluster II comprises a domain known as CL-11-1/2 that spans the amino-terminal flanking epidermal growth Factor repeat E4 and the LDLRA domains C3-C7. This CL-ll-1/2 domain interacts with Factor VIII (see Neels, J.G. et al., supra).
- the present invention also relates to a pharmaceutical composition that comprises at least one peptide wherein said peptide comprises the amino acid sequence as defined in any of SEQ ID Nos. 1 , 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity, or an antibody which specifically binds to one or more epitopes within said amino acid sequences, and a physio-logically acceptable excipient, carrier, diluent and/or stabilizator.
- compositions according to the invention can comprise one or more peptides useful for the present invention or one or more antibodies useful for the invention or derivatives thereof. Pharmaceutical compositions according to the invention can also comprise one of more further therapeutic or prophylactic active ingredients. In one embodiment, the pharmaceutical composition comprises one or more peptides useful for the present invention. In another embodiment, the pharmaceutical composition comprises or one or more antibodies useful for the invention directed against said peptides. When the pharmaceutical composition comprises one or more antibodies useful for the invention, said pharmaceutical composition may further contain Factor VIII. The Factor VIII in such a pharmaceutical composition can be derived from any naturally occurring, synthetic or recombinant source.
- a peptide and/or antibody useful for the invention can be formulated as a solution, suspension, emulsion, or lyophilised powder in association with a pharmaceutically acceptable vehicle such as one or more excipient(s), carrier(s), diluent(s) and stabilizer(s).
- a pharmaceutically acceptable vehicle such as one or more excipient(s), carrier(s), diluent(s) and stabilizer(s).
- Suitable carriers include, but are not limited to, diluents or fillers, sterile aqueous media and various non-toxic organic solvents. Examples of such vehicles are water, saline, Ringer's solution, dextrose solutions, and human serum albumin solutions. Liposomes and non-aqueous vehicles such as fixed oils may also be used.
- the vehicle or lyophilizate may contain additives that maintain the isotonicity, for example, NaCI, sucrose, mannitol, and stability, for example buffers and/or preservatives.
- Suitable pharmaceutically acceptable vehicles are described in Remington's Pharmaceutical Sciences by A. Osol, a standard textbook in this field (incorporated by reference).
- the compositions may be formulated in the form of tablets, capsules, powders, aqueous suspensions or solutions, injectable solutions and the like.
- the pharmaceutical composition according to the invention is lyophilised.
- the administration of the pharmaceutical composition according to the invention method of this invention should preferably be carried out employing a dosage regimen that ensures maximum therapeutic response until improvement is achieved.
- the dose will be dependent on the molecular size of the peptide used.
- the dosage for intravenous administration may vary between approximately 0.1 and 1000 mg/kg, preferably between 1 and 500 mg/kg, and most preferably between 10 and 100 mg/kg.
- the dose may be increased accordingly.
- the dose may be substantially higher, bearing in mind, of course, that appropriate dosage may also be dependent on the patient's general health, age and other factors that may influence the response to the drug.
- the drug may be administered by continuous infusion, or at regular intervals of approximately 4 to 50 hours to maintain the therapeutic effect at the desired level.
- the pharmaceutical composition according to the invention can be in the form of a single component preparation or can exist in combination with one or more other components in a kit.
- the pharmaceutical composition according to the invention is intended for administration to mammals, preferably humans.
- a peptide useful for the present invention is intended for administration to a particular mammal, for example a human, then it is preferred that said peptide is derived from that particular mammal.
- the antibody useful for the invention is intended for administration to a particular mammal, for example a human, then it is preferred that said antibody was generated using an epitope derived from that particular mammal.
- an antibody useful for the invention that is intended for administration to a human is a human or humanized antibody.
- a peptide useful for the present invention, an antibody useful for the invention as well as derivatives of these and pharmaceutical compositions comprising said peptides, antibodies and derivatives can be administered to a subject by any means that enables said peptide, antibody or derivatives thereof to reach the site of action in the body.
- said peptides, antibodies and derivatives thereof and pharmaceutical compositions comprising said peptides, antibodies and derivatives thereof according to the invention are administered parenterally, i.e. intravenously, subcutaneously, or intramuscularly.
- the pharmaceutical preparation according to the invention can be used to treat any subject in need of the administration of an agent that inhibits Factor VIII interaction with LRP, decreases Factor VIII degradation or prolongs Factor VIII half-life, in particular for the prevention or treatment of patients that have a blood coagulation disorder.
- a blood coagulation disorder can be at least in part caused by a deficiency, for example a genetic or inborn deficiency or an acquired deficiency, in Factor VIII.
- Such a blood coagulation disorder can also be at least in part caused by a deficiency, for example a genetic or inborn deficiency or an acquired deficiency, in any other protein involved in the coagulation pathway, including Factor IX, Factor V, Factor X or von Willebrand Factor.
- a deficiency for example a genetic or inborn deficiency or an acquired deficiency, in any other protein involved in the coagulation pathway, including Factor IX, Factor V, Factor X or von Willebrand Factor.
- said blood coagulation disorder is Haemophilia A or von Willebrand's disease.
- the present invention further relates to the use of a peptide comprising an amino acid as defined in any of SEQ ID No. 1, 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity, or of an antibody which specifically binds to one or more epitopes within said amino acid sequences for the preparation of a medicament for the treatment of a blood coagulation disorder.
- the blood coagulation disorder is haemophilia A or von Willebrand's disease.
- the pharmaceutical preparation according to the invention can also be used for the prevention or treatment of patients that have temporary impairment of their thrombolytic or fibrinolytic systems, for example, for patients directly before, during or after an operation or surgical procedure.
- the present invention also relates to the use of a peptide comprising an amino acid sequence as defined in any of SEQ ID Nos. 1, 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity, or an antibody which specifically binds to one or more epitopes within said amino acid sequences to decrease Factor VIII degradation in a biological fluid.
- the present invention provides a method to decrease Factor VIII degradation in a biological fluid, wherein a peptide as defined in any of SEQ ID Nos. 1, 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity, or an antibody which specifically binds to one or more epitopes within said amino acid sequences is added to said biological fluid.
- a “biological fluid” as used herein includes a fluid isolated from a mammal, such as blood, or a fraction thereof, such as plasma or serum, as well as the medium or fractions thereof obtained from the culture of eukaryotic or prokaryotic cells, cell lines or tissues.
- an amount of said peptide or said antibody is added which is sufficient to decrease Factor VIII degradation by at least 10%, more preferably by at least 20%, still more preferably by at least 50% and most preferably by essentially 100%.
- the present invention further relates to the use, and related method, of a peptide comprising an amino acid sequence as defined in any of SEQ ID Nos. 1, 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity, or of an antibody which specifically binds to one or more epitopes within said amino acid sequences to prolong Factor VIII half-life in a biological fluid.
- a peptide comprising an amino acid sequence as defined in any of SEQ ID Nos. 1, 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity
- an antibody which specifically binds to one or more epitopes within said amino acid sequences to prolong Factor VIII half-life in a biological fluid.
- an amount of said peptide or said antibody is added which is sufficient to prolong Factor VIII half-life in a biological fluid at least 2-fold, more preferably at least 5-fold, and most preferably at least 10-fold.
- the present invention further relates to the use, and the related method, of a peptide as defined in any of SEQ ID Nos. 1 , 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity, or an antibody which specifically binds to one or more epitopes within said amino acid sequences to inhibit the interaction of Factor VIII with LRP in a biological fluid.
- a peptide as defined in any of SEQ ID Nos. 1 , 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity
- an antibody which specifically binds to one or more epitopes within said amino acid sequences to inhibit the interaction of Factor VIII with LRP in a biological fluid.
- an amount of said peptide or said antibody is added which is sufficient to achieve an inhibition extent of Factor VIII to with LRP of at least 10%, preferably at least 20%, most preferably at least 50%.
- the present invention further relates to a method of treating a patient suffering from a blood coagulation disorder wherein said method comprises administering to said patient an effective amount of a peptide as defined in any of SEQ ID Nos. 1, 2, 3 or 4 as derived from Factor VIII, but not having any substantial Factor VIII activity, or an antibody which specifically binds to one or more epitopes within said amino acid sequences to inhibit the interaction of Factor VIII with LRP or a pharmaceutical composition comprising one or more of said peptide or one or more of said antibody.
- CNBr-Sepharose 4B was from Amersham Pharmacia Biotech. Microtiter plates (Maxisorp), cell culture flasks, Optimem I medium, fetal calf serum (FCS), penicillin, and streptomycin were from Life Technologies (Life Technologies Inc., Breda, The Netherlands).
- Grace's Insect medium (TNM-FH) and Insect-XPRESS medium were purchased from BioWhittaker (Alkmaar, The Netherlands).
- Proteins- Plasma-derived FVIII light chain and its Factor Xa-cleaved derivative were prepared as described previously (Lenting, P. J., Donath, M. J. S. H., van Mourik, J. A., and Mertens, K. (1994) J. Biol. Chem. 269, 7150-7155; Donath, M. S. J. H., Lenting, P. J., van Mourik, J. A., and Mertens, K. (1995) J. Biol. Chem. 270, 3648-3655; incorporated herein by reference).
- Anti-FVIII monoclonal antibodies CLB-CAg A, CLB-CAg 117 and CLB-CAg 12 have been described previously (Lenting, P. J. et al., (1994), supra; Leyte, A., Mertens, K., Distel, B., Evers, R. F., de Keyzer-Nellen, M. J., Groenen-van Dooren, M. M., de Bruin, J., Pannekoek, H., van Mourik, J. A, and Verbeet, M. P. (1989) Biochem. J. 263, 187-194; incorporated herein by reference).
- the anti-FVa light chain monoclonal antibody CLB-FV 5 was obtained by standard hybridoma techniques.
- Single-chain domain variable antibody fragments directed against the light chain of FVIII were expressed in Escherichia coli strain TG1 and purified by metal- chelate chromatography (Qiagen, Hilden, Germany) as described previously (32- 34), with the exception that scFvs KM36, KM41 , and KM33 were eluted in 150 mM NaCI, 5 mM CaCI 2 , 100 mM Imidazole, and 20 mM Hepes (pH 7.4).
- Synthetic peptides encompassing the human FVIII regions Trp1707_A r g1721 (WDYGMSSPHVLRNR) (SEQ ID NO:5), Lys1 ⁇ 04.
- ys 1818 KNFVKPNETKTYFWK
- Tyr 1815 -Ala 18 34 YFWKVQHHMAPTKDEFDCKA
- His 1822 -Ala1 ⁇ 34 HMAPTKDEFDCKA
- a 1901 (TENMERNCRA) SEQ ID NO:7)
- Lys 1972 (TVRKKEEYK) (SEQ ID NO:9), Lys 2 0 9 -Gly 2 0 57 (KLARLHYSG) (SEQ ID NO:10), and Asp 2 10 ⁇ _Gly 2 117 (DGKKWQTYRG) (SEQ ID NO:11) were synthesized by Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry by the manual "T-bag”-method (Houghton, R.A. (1985) PNAS U.S.A.
- Peptides were more than 95% pure as determined by high-pressure-liquid- chromatography (HPLC) analysis, and their identity was confirmed by mass spectrometry.
- Purified placenta-derived LRP was obtained as described (Moestrup, S. K., and Gliemann, J. (1991) J. Biol. Chem. 266, 14011-14017; incorporated herein by reference).
- Gluthatione S-transferase-fused receptor- associated protein (GST-RAP) was was expressed in Escherichia coli strain DH5 ⁇ and purified employing gluthatione-sepharose as described (Herz, J., Goldstein, J. L, Strickland, D. K., Ho, Y. K., and.
- FVIII-del The plasmid pCLB-BPVdB695 encoding the FVIII B domain deletion variant, FVIII-del (868-1562) has been described previously (Mertens, K., Donath, M. J. S. H., van Leen, R. W., de Keyzer-Nellen, M. J. M., Verbeet, M. P., Klaasse Bos, J. M., Leyte, A., and van Mourik, J. A. (1993) Br. J. Haematol. 85, 133-142; incorporated herein by reference), and was used as a template to construct the plasmid coding for FVIII/FV18 -1818 chimera.
- Oligonucleotide primers derived from the FVIII light chain sequence containing the FVIII/FV codon replacements were employed to construct the plasmids using the Overlap Extension PCR mutagenesis method (Tao, B. Y., and Lee K. C. P. (1994) PCR Technology Current Innovations (Griffin, H. G., and Griffin, A. M., eds), 71-72, CRC Press, Boca Raton, FL; incorporated herein by reference). Sequence analysis was performed to verify the presence of the mutations in the plasmid.
- FVIII encoding plasmids into murine fibroblasts (C127) cells was performed as described previously (Mertens, K., et al., (1993), supra).
- Stable cell lines expressing wild-type FVIII or FVIII/FV 1811"1818 chimera were maintained in 1-1 cell factories in RPM1 1640 medium, supplemented with 5% FCS, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 1 ⁇ g/ml amphotericin B and 0.8 ⁇ g/ml desoxycholate.
- FVIII containing medium was harvested three times a week.
- FVIII light chains were prepared by incubating purified FVIII/FVl ⁇ H-l ⁇ l ⁇ chimera and wild-type FVIII in a buffer containing 40 mM EDTA, 100 mM NaCI, and 50 mM Tris (pH 7.4) for 4 h at 25°C. Subsequently, FVIII/FV1811-1818 light chain chimera and wild-type FVIII light chain were purified employing Q-Sepharose chromatography. Recombinant proteins were eluted in a buffer containing 1 M NaCI and 50 mM Tris (pH 7.4), dialyzed against 150 mM NaCI and 50 mM Tris (pH 7.4), and stored at 4 °C.
- the construction of the plasmid encoding the recombinant C2 domain has been described previously (Fijnvandraat, K., et al., (1998) supra).
- the plasmid pACgp67b-H/s-a3-A3-C1 encoding the FVIII a3-A3-C1 fragment (i.e.
- residues Gl u 1649_Asn 2 1 72 was constructed by polymerase chain reaction employing the oligonucleotide primers, 5'-TTACTCGAGGAAATAACTCGTACTACTC-3' (sense) (SEQ ID NO-13), and, 5'-AATGCGGCCGCTTCAATTTAAATCACAGCCCAT-3' (anti-sense) (SEQ ID NO:14), using pCLB-BPVdB695 as a template (Mertens, K., et al., (1993), supra). The amplified DNA fragment was purified, digested with Xhol and Notl, and ligated into pBluescript. The resulting construct was verified by sequencing.
- pBluescript-a3-A3-C1 was digested with Espl and Notl, and the obtained fragment was purified and ligated into the Espl/Notl digested pACgp67b-80K plasmid (Fijnvandraat, K., Turenhout, E. A. M., van den Brink, E. N., ten Cate, J. W., van Mourik, J. A., Peters, M., and Voorberg, J. (1997) Blood 89, 4371-4377; incorporated herein by reference).
- a DNA fragment encoding a poly His-tag (5'-
- ATTGGATCCGGCCATCATCATCATCATGGCGGCAGCCCCCGCAGCTTTC AAAAGCCCGGGGCCATGGGA-3') (SEQ ID NO:15) was digested with BamHI and Ncol and cloned within the BamHI/Ncol digested pACgp67b-a3-A3-C1 plasmid.
- pACgp67b-a3-A3-C1 plasmid pACgp67b-a3-A3-C1 plasmid.
- baculovirus expression system recombinant a3-A3-C1 and C2 fragments were obtained by infection of insect cells as described (Fijnvandraat, K., et al., (1998), supra).
- the a3-A3-C1 fragment was purified from Insect-XPRESS medium employing immunoaffinity chromatography, using the anti-A3 domain antibody CLB-CAg A coupled to CNBr-Sepharose 4B as affinity matrix.
- CLB-CAg A-Sepharose was incubated with medium containing the a3-A3-C1 fragment for 16 h at 4 °C. After binding, the immunoaffinity matrix was collected and washed with a buffer containing 1 M NaCI and 50 mM Tris (pH 7.4), and eluted with 150 mM NaCI, 55% (v/v) Ethylene Glycol, and 50 mM Lysine (pH 11).
- Elution fractions were immediately neutralized with 1 M Imidazole (pH 6.0), dialyzed against 150 mM NaCI, 50% (v/v) Glycerol, and 50 mM Tris (pH 7.4), and stored at -20 °C.
- the recombinant C2 domain was purified employing the same immunoaffinity chromatography technique, except that anti-C2 domain antibody CLB-CAg 117 was used instead of CLB-CAg A.
- FV Factor Va Light Chain- Human Factor V
- Thrombin was inactivated by Hirudin (Sigma-Aldrich, St.Louis, MO) and FVa light chain was purified employing immunoaffinity chromatography, using CNBr-Sepharose 4B coupled with the anti-Factor V light chain monoclonal antibody CLB-FV 5 (5 mg/ml).
- the immunoaffinity matrix was washed with 100 mM NaCI, 25 mM EDTA, and 50 mM Tris (pH 7.4) and eluted with 100 mM NaCI, 5 mM CaCI 2 , 55% (v/v) Ethylene Glycol, and 50 mM Tris (pH 7.4).
- Purified FVa light chain was dialyzed against 150 mM NaCI, 5 mM CaCI 2 , 50% (v/v) glycerol, and 50 mM Tris (pH 7.4), and stored at -20 °C.
- LRP Fragments- Recombinant LRP clusters II and IV were expressed in BHK cells, using Optimem I medium supplemented with 100 units/ml penicillin and 100 ⁇ g/ml streptomycin (Neels, J. G., et al., (1999) supra). After harvesting of the medium, CaC was added to a final concentration of 10 mM. Purification of LRP clusters II and IV from conditioned media was performed by a single purification step, using GST-RAP coupled to CNBr-Sepharose 4B as affinity matrix.
- the matrix was collected in a column, washed with a buffer containing 150 mM NaCI, 5 mM CaCI 2 , and 50 mM Hepes (pH 7.4), and eluted with 150 mM NaCI, 20 mM EDTA, and 50 mM Hepes (pH 7.4).
- purified LRP cluster preparations were concentrated employing Centricon 10 concentrators (Millipore, Bedford, MA) by successive rounds of centrifugation for 1 h at 4000 x g at 4 °C. Finally, the preparations were dialyzed against 150 mM NaCI, 2 mM CaCI 2 , 0.005% (v/v) Tween® 20, and 20 mM Hepes (pH 7.4), and stored at 4 °C.
- FVIII light chain or its derivatives were incubated at various concentrations in a volume of 50 ⁇ l in a buffer containing 150 mM NaCI, 5 mM CaCI 2 , 1% (w/v) HSA, 0.1% (v/v) Tween® 20, and 50 mM Tris (pH 7.4) for 2 h at 37 °C.
- Bound ligand was detected by incubating with peroxidase-conjugated monoclonal antibody CLB-CAg 12 in the same buffer for 15 min at 37 °C. Antibody CLB-CAg 12 did not interfere with binding of FVIII fragments to LRP or LRP clusters (data not shown).
- FVIII light chain 25 nM was incubated with wells containing immobilized LRP clusters, either in the presence or absence of serial dilutions of competitor in a volume of 50 ⁇ l for 2 h at 37 °C. Residual FVIII binding was detected as described above. Data were corrected for binding to empty microtiter wells, which was less than 5% relative to binding to wells containing immobilized LRP clusters.
- the kinetics of protein interactions was determined by surface plasmon resonance (SPR) analysis, employing a BIAcoreTM2000 biosensor system (Biacore AB, Uppsala, Sweden).
- LRP (16 fmol/mm 2 ), FVIII light chain (71 fmol/mm 2 ), a3-A3-C1 fragment (67 fmol/mm 2 ), FVa light chain (76 fmol/mm 2 ), or scFv EL14 (67 fmol/mm 2 ) were covalently coupled to the dextran surface of an activated CM5-sensor chip via primary amino groups, using the amine-coupling kit as prescribed by the supplier.
- association (k on ) and dissociation (k 0 ff) rate constants were determined by using the BIAevaluation software 3.1 (Biacore AB, Uppsala, Sweden). Data were corrected for bulk refractive index changes and fitted by nonlinear regression analysis according to a two-site binding model. Equilibrium dissociation constants (k ⁇ j) were calculated from the ratio k 0 ff/k on . The /t ⁇ value for low-affinity interactions was estimated using steady-state affinity analysis by using BIAevaluation software.
- FVIII light chain 50 nM was incubated with immobilized LRP (16 fmol/mm 2 ) either in the presence or absence of serial dilutions of competitor for 2 min, at a flow rate of 20 ⁇ l/min at 25 °C.
- LRP cluster II (25-125 nM) was passed over separate channels with immobilized FVI I I/FV1811-1818 ⁇ ⁇ c hain chimera or wild-type recombinant FVIII light chain, respectively, and one control (scFv EL14-coated) channel in 150 mM NaCI, 2 mM CaCI 2 , 0.005% (v/v) Tween® 20, and 20 mM Hepes (pH 7.4) for 2 min, at a flow rate of 20 ⁇ l/min at 25 °C.
- Affinity constants (K ) were calculated from the ratio k 0 f k on .
- the interaction between C2 domain and LRP was assessed employing steady-state affinity analysis. Data are based on three to six measurements using at least five different concentrations for each measurement. Data represent the average ⁇ S.D.)
- the synthetic peptides comprised residues Trp1 7 ⁇ 7 - Arg1721 ( Lys1 8 0 4 -Lys1 ⁇ 1 , Tyr1815_ A ] a 1834 > His 1822. ⁇ 1834, T hr1 ⁇ 92. Ala1901 , GI U 908.HJ S 1919, Thr 1964. ⁇ 1972, ⁇ 2049.6 ⁇ 2057, and A sp 2 10 ⁇ . G
- FVIII light chain (25 nM) was incubated with immobilized LRP cluster II (1 pmol/well) in a volume of 50 ⁇ l in 150 mM NaCI, 5 mM CaCI2, 1% (w/v) HSA, 0.1% Tween® 20, and 50 mM Tris (pH 7.4) in the presence or absence of various concentrations of synthetic peptide (0-1 mM) for 2 h at 37 °C.
- scFv KM36 The first scFv, referred to as scFv KM36, is directed against a region within Gln1 778 -Asp1 84 0 i but does not require residues Arg1 ⁇ 03.
- the second scFv is directed against region Arg1 ⁇ 03.
- the amino acid sequence of the heavy chain of scFv KM41 as well as the corresponding DNA sequence is shown in SEQ ID NO: 16.
- the amino acid sequence of the light chain of scFv KM41 as well as the corresponding DNA sequence is shown in SEQ ID NO:18.
- the heavy chain and light chain of KM41 can be bound over a peptide linker (SEQ ID NO:24) and can have a histidine tag at the C-terminus.
- the amino acid sequence of the expressed scFv KM41 protein is depicted in SEQ ID NO:25.
- the third scFv, called scFv KM33 is similar to scFv KM41 except that it does not require A3 domain region 1778-1818 for its interaction with FVIII light chain (van den Brink et al., (2001), supra; WO 99/58680 supra).
- the amino acid sequence of the heavy chain of scFv KM33 as well as the corresponding DNA sequence is shown in SEQ ID NO:20.
- the amino acid sequence of the light chain of scFv KM33 as well as the corresponding DNA sequence is shown in SEQ ID NO:22.
- the heavy chain and light chain of KM33 can be bound over a peptide linker (SEQ ID NO:24) and can have a histidine tag at the C-terminus.
- SEQ ID NO:24 The amino acid sequence of the expressed scFv KM33 protein is depicted in SEQ ID NO:26.
- scFv KM36 did not affect the interaction between FVIII light chain and immobilized LRP cluster II.
- the presence of scFv KM41 inhibited the binding of FVIII light chain to LRP cluster II (Fig. 4A).
- the effect of scFv KM41 on the interaction between FVIII light chain and LRP was further studied employing SPR analysis. As shown in Fig.
- the FVIII Light Chain Sequence Glu 1 811 -Lys 1 '818 Contains a Binding Site for LRP-
- ⁇ yr 1815.Aia1 ⁇ 34 are effective inhibitors of FVIII procoagulant activity by interfering with the assembly of the FVIIIa-FIXa complex (Lenting, P. J., et al., (1996) supra; WO 96/41816, supra), while the scFvs KM33 and KM41 are effective inhibitors of FVIII procoagulant activity by interfering with the assembly of the FVIIIa-FIXa complex (Lenting, P.
- the isolated chimera (FVIII/FV 11-1818) was compared to wild-type recombinant FVIII light chain in terms of association with LRP cluster II, employing SPR analysis. As shown in Fig. 6, LRP cluster II displayed a 2-3 fold reduced association with immobilized FVIII/FV1811-1818 as compared to wild-type FVIII light chain.
- the isolated chimera (FVIII/FV 811-1818) was then evaluated for its ability to interact with scFv KM41 , employing SPR analysis. As demonstrated in Fig. 7, scFv KM41 did not recognize the immobilized FVIII/FV 1811"1818 chimera, whereas it readily reacted with immobilized wild-type recombinant FVIII light chain. These observations indicate that FVIII A3 domain region Glu1811-Lys181 ⁇ contains residues critical for binding to scFv KM41. These data demonstrate that FVIII light chain region Glu1 ⁇ 1 -Lys1 ⁇ 1 ⁇ serves an important role in the assembly of the LRP-FVIII light chain complex.
- A3 domain region Glu1811-Lys181 ⁇ of the FVIII light chain contributes to the high affinity interaction with LRP.
- _y S 1818 a nd Tyr1 ⁇ 15_Ala1 ⁇ 3 4 affected the interaction between FVIII light chain and LRP cluster II (Table II).
- a FVIII light chain chimera in which region Glu1 ⁇ 11-Lys1 ⁇ 1 ⁇ j s replaced by corresponding residues of FV, displayed a reduction in association to LRP cluster II as compared to the wild-type FVIII light chain (Fig. 6).
- a recombinant scFv antibody fragment directed against region Glu 1811 -Lys 1818 . inhibited binding of FVIII light chain to LRP or its cluster II fragment (Fig.4).
- LRP LRP ligands
- RAP lipoprotein lipase
- ⁇ 2 - macroglobulin ligands
- positively charged residues at the ligand surface are involved in the interaction with LRP (Melman, L., Cao, Z. F., Rennke, S., Paz Marzolo, M., Wardell, M. R., and Bu, G. (2001) J. Biol. Chem. 276, 29338-29346; Chappell, D.A., Fry, G. L., Waknitz, M. A., Muhonen, L. E., Pladet, M. W., Iverius, P. H., and Strickland, D. K.
- FVIII A3 domain region Glu1 ⁇ 11-Lys1 ⁇ 1 ⁇ contains two exposed positively charged lysine residues at positions 1813 and 1818.
- these lysine residues appear to be unique for the FVIII A3 domain (Church, W.R., et al. (1984), supra).
- Replacement of FVIII residues Glu1811-Lys1818 for the corresponding residues of FV resulted in impaired binding to LRP cluster II (Fig. 6).
- an anti-C2 domain monoclonal antibody (ESH4) completely inhibits the interaction between FVIII light chain and LRP (Lenting, P.J. et al., (1999), supra; WO 00/28021, supra).
- the mechanism by which antibody ESH4 inhibits LRP binding is not yet elucidated. Because the anti-C2 antibody does not require region Glu181 -Lys1818 for its interaction with FVIII light chain (Scandella, D., Gilbert, G. E., Shima, M., Nakai, H., Eagleson, C, Felch, M., Prescott, R., Rajalakshmi, K. J., Hoyer, L W., and Saenko, E. (1995) Blood 86, 1811-1819; incorporated herein by reference), it is unlikely that ESH4 competes with LRP for binding to the same site in the A3 domain. Therefore, one of the mechanisms that could contribute to the inhibition includes sterical interference.
- scFv KM41 only partially inhibits the interaction between FVIII light chain and LRP (Fig. 4). This might be due to the relative small size of a scFv antibody fragment (« 30 kDa) as compared to a complete antibody ( « 150 kDa).
- region Glu1811-Lys181 8 other surface exposed structural elements within the A3-C1 domains (i.e. residues Ala1 722 - Asn 2 1 72 ) contribute to the assembly of the LRP-FVIII light chain complex. This is in line with the observation that the FVIU/FV1811-1818 light chain chimera demonstrated residual binding to LRP cluster II (Fig. 6).
- the Glu1811-Lys 18 18 region within the A3 domain of FVIII light chain is part of a larger segment that is exposed to the protein surface (i.e. residues Glu 804 -Lys1 ⁇ 1 ⁇ ) (Lenting, P. J., et al., (1996), supra). Besides the lysine residues at positions Lys ⁇ 3 and Lys1 ⁇ 1 ⁇ , this region contains two additional FVIII unique lysine residues at positions Lys1 ⁇ 04 anc j
- a second control group of animals received human FVIII co-injected with a scFv fragment (KM38) binding to Factor VIII on a site different than LRP. With these animals, the same results as with the Factor VIII control group were obtained (Fig. ⁇ ).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT03725109T ATE463514T1 (en) | 2002-04-29 | 2003-04-28 | ANTAGONISTS OF THE INTERACTION BETWEEN FACTOR VIII AND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß) |
US10/512,907 US8586538B2 (en) | 2002-04-29 | 2003-04-28 | Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII |
JP2004501452A JP2005535588A (en) | 2002-04-29 | 2003-04-28 | Antagonists of the interaction between factor VIII and low density lipoprotein receptor-related proteins |
AU2003227687A AU2003227687B2 (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein |
EP03725109A EP1497330B1 (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
DK03725109.7T DK1497330T3 (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein |
DE60332011T DE60332011D1 (en) | 2002-04-29 | 2003-04-28 | ANTAGONISTS OF INTERACTION BETWEEN FACTOR VIII AND LRP (LOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN) |
CA2484155A CA2484155C (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37635102P | 2002-04-29 | 2002-04-29 | |
US60/376,351 | 2002-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003093313A2 true WO2003093313A2 (en) | 2003-11-13 |
WO2003093313A3 WO2003093313A3 (en) | 2004-07-29 |
Family
ID=29401334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/004425 WO2003093313A2 (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
Country Status (10)
Country | Link |
---|---|
US (1) | US8586538B2 (en) |
EP (1) | EP1497330B1 (en) |
JP (2) | JP2005535588A (en) |
AT (1) | ATE463514T1 (en) |
AU (1) | AU2003227687B2 (en) |
CA (1) | CA2484155C (en) |
DE (1) | DE60332011D1 (en) |
DK (1) | DK1497330T3 (en) |
ES (1) | ES2343681T3 (en) |
WO (1) | WO2003093313A2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1454632A1 (en) * | 2003-02-07 | 2004-09-08 | Aventis Behring GmbH, Intellectual Property/Legal | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides |
WO2006003183A1 (en) * | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptides for blocking fviii inhibitors |
WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
US7763244B2 (en) | 2002-07-01 | 2010-07-27 | Human Genome Sciences, Inc. | Antibodies that specifically bind to Reg IV |
WO2012035050A2 (en) | 2010-09-15 | 2012-03-22 | Novo Nordisk A/S | Factor viii variants having a decreased cellular uptake |
US8252287B2 (en) | 2006-08-31 | 2012-08-28 | Chugai Seiyaku Kabushiki Kaisha | Blood coagulation factor VIII activation-enhancing antibodies |
WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
US8575104B2 (en) | 2008-06-24 | 2013-11-05 | Csl Behring Gmbh | Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life |
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
EP2796145A1 (en) | 2013-04-22 | 2014-10-29 | CSL Behring GmbH | Complex |
WO2016000039A1 (en) | 2014-07-02 | 2016-01-07 | Csl Limited | Modified von willebrand factor |
WO2016142288A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
WO2016188907A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
WO2016188905A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
WO2017117631A1 (en) | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated truncated von willebrand factor |
US9718883B2 (en) | 2003-09-10 | 2017-08-01 | Amgen Fremont Inc. | Antibodies to M-CSF |
WO2018087271A1 (en) | 2016-11-11 | 2018-05-17 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
WO2018087267A1 (en) | 2016-11-11 | 2018-05-17 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
US10808023B2 (en) | 2016-01-07 | 2020-10-20 | CSL Behring Lengnau AG | Mutated von Willebrand factor |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0913374A2 (en) * | 2008-06-04 | 2015-11-24 | Bayer Healthcare Llc | fviii muteins for treatment of von willebrand disease |
JP5394864B2 (en) * | 2009-09-10 | 2014-01-22 | アスモ株式会社 | motor |
WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041816A1 (en) * | 1995-06-12 | 1996-12-27 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69939379D1 (en) * | 1998-05-08 | 2008-10-02 | Sanquin Bloedvoorziening | TEMPERATURE FOR THE DIAGNOSIS AND TREATMENT OF HAEMOPHILIA A PATIENT |
AU775529B2 (en) * | 1998-11-10 | 2004-08-05 | Stichting Sanquin Bloedvoorziening | A factor VIII-polypeptide with factor VIII:C-activity |
AT409335B (en) * | 1998-11-10 | 2002-07-25 | Immuno Ag | PHARMACEUTICAL PREPARATION CONTAINING A RECEPTOR ANTAGONIST FOR THE TREATMENT OF BLOOD COagulation disorders |
-
2003
- 2003-04-28 DE DE60332011T patent/DE60332011D1/en not_active Expired - Lifetime
- 2003-04-28 JP JP2004501452A patent/JP2005535588A/en active Pending
- 2003-04-28 AT AT03725109T patent/ATE463514T1/en active
- 2003-04-28 ES ES03725109T patent/ES2343681T3/en not_active Expired - Lifetime
- 2003-04-28 AU AU2003227687A patent/AU2003227687B2/en not_active Ceased
- 2003-04-28 WO PCT/EP2003/004425 patent/WO2003093313A2/en active Application Filing
- 2003-04-28 EP EP03725109A patent/EP1497330B1/en not_active Expired - Lifetime
- 2003-04-28 CA CA2484155A patent/CA2484155C/en not_active Expired - Lifetime
- 2003-04-28 US US10/512,907 patent/US8586538B2/en active Active
- 2003-04-28 DK DK03725109.7T patent/DK1497330T3/en active
-
2010
- 2010-06-07 JP JP2010130425A patent/JP2010202664A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041816A1 (en) * | 1995-06-12 | 1996-12-27 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation |
Non-Patent Citations (5)
Title |
---|
BOVENSCHEN N ET AL.: "Low Density Lipoprotein Receptor-related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 11, 14 March 2003 (2003-03-14), pages 9370-9377, XP002264413 * |
LENTING P J ET AL: "THE SEQUENCE GLU-1811-LYS-1818 OF HUMAN BLOOD COAGULATION FACTOR VIII COMPRISES A BINDING SITE FOR ACTIVATED FACTOR IX" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 4, 26 January 1996 (1996-01-26), pages 1935-1940, XP002017258 ISSN: 0021-9258 cited in the application * |
NEELS JG ET AL.: "Interaction Between Factor VIII and LDL Receptor-related Protein" TRENDS IN CARDIOVASCULAR MEDICINE, vol. 10, 2000, pages 8-14, XP002264412 * |
SAENKO EL ET AL.: "Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 53, 31 December 1999 (1999-12-31), pages 37685-37692, XP002264411 cited in the application * |
See also references of EP1497330A2 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763244B2 (en) | 2002-07-01 | 2010-07-27 | Human Genome Sciences, Inc. | Antibodies that specifically bind to Reg IV |
EP1454632A1 (en) * | 2003-02-07 | 2004-09-08 | Aventis Behring GmbH, Intellectual Property/Legal | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides |
US10280219B2 (en) | 2003-09-10 | 2019-05-07 | Amgen Fremont Inc. | Antibodies to M-CSF |
US9718883B2 (en) | 2003-09-10 | 2017-08-01 | Amgen Fremont Inc. | Antibodies to M-CSF |
WO2006003183A1 (en) * | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptides for blocking fviii inhibitors |
US8765915B2 (en) | 2006-02-06 | 2014-07-01 | Csl Behring Gmbh | Modified coagulation factor VIIa with extended half-life |
US8252287B2 (en) | 2006-08-31 | 2012-08-28 | Chugai Seiyaku Kabushiki Kaisha | Blood coagulation factor VIII activation-enhancing antibodies |
US8754194B2 (en) | 2006-12-22 | 2014-06-17 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
EP3231440A1 (en) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
US8575104B2 (en) | 2008-06-24 | 2013-11-05 | Csl Behring Gmbh | Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life |
EP2865760A1 (en) | 2008-06-24 | 2015-04-29 | CSL Behring GmbH | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
US9290561B2 (en) | 2008-06-24 | 2016-03-22 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2012035050A2 (en) | 2010-09-15 | 2012-03-22 | Novo Nordisk A/S | Factor viii variants having a decreased cellular uptake |
EP3466968A1 (en) | 2010-09-15 | 2019-04-10 | Stichting Sanquin Bloedvoorziening | Factor viii variants having a decreased cellular uptake |
WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
US9458223B2 (en) | 2012-02-15 | 2016-10-04 | Csl Behring Gmbh | Von willebrand factor variants having improved factor VIII binding affinity |
US9878017B2 (en) | 2013-04-22 | 2018-01-30 | Csl Ltd. | Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto |
EP2796145A1 (en) | 2013-04-22 | 2014-10-29 | CSL Behring GmbH | Complex |
WO2014173873A1 (en) | 2013-04-22 | 2014-10-30 | Csl Behring Gmbh | Complex |
US10253088B2 (en) | 2014-07-02 | 2019-04-09 | CSL Behring Lengnau AG | Modified von Willebrand Factor |
WO2016000039A1 (en) | 2014-07-02 | 2016-01-07 | Csl Limited | Modified von willebrand factor |
US11155601B2 (en) | 2015-03-06 | 2021-10-26 | CSL Behring Lengnau AG | Modified von Willebrand factor having improved half-life |
WO2016142288A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
US10688157B2 (en) | 2015-05-22 | 2020-06-23 | CSL Behring Lengnau AG | Truncated von Willebrand factor polypeptides for treating hemophilia |
EP4089109A2 (en) | 2015-05-22 | 2022-11-16 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
US11564976B2 (en) | 2015-05-22 | 2023-01-31 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand Factor |
WO2016188907A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
WO2016188905A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
US10772936B2 (en) | 2015-05-22 | 2020-09-15 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
US10905747B2 (en) | 2015-05-22 | 2021-02-02 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
US10808023B2 (en) | 2016-01-07 | 2020-10-20 | CSL Behring Lengnau AG | Mutated von Willebrand factor |
US10806774B2 (en) | 2016-01-07 | 2020-10-20 | CSL Behring Lengnau AG | Mutated truncated von Willebrand Factor |
WO2017117631A1 (en) | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated truncated von willebrand factor |
WO2018087267A1 (en) | 2016-11-11 | 2018-05-17 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
WO2018087271A1 (en) | 2016-11-11 | 2018-05-17 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
US11814421B2 (en) | 2016-11-11 | 2023-11-14 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
US11890327B2 (en) | 2016-11-11 | 2024-02-06 | CSL Behring Lengnau AG | Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Also Published As
Publication number | Publication date |
---|---|
JP2010202664A (en) | 2010-09-16 |
DE60332011D1 (en) | 2010-05-20 |
EP1497330A2 (en) | 2005-01-19 |
JP2005535588A (en) | 2005-11-24 |
CA2484155A1 (en) | 2003-11-13 |
EP1497330B1 (en) | 2010-04-07 |
AU2003227687B2 (en) | 2009-10-15 |
WO2003093313A3 (en) | 2004-07-29 |
ATE463514T1 (en) | 2010-04-15 |
AU2003227687A1 (en) | 2003-11-17 |
US20080219983A1 (en) | 2008-09-11 |
DK1497330T3 (en) | 2010-06-14 |
ES2343681T3 (en) | 2010-08-06 |
CA2484155C (en) | 2015-10-13 |
US8586538B2 (en) | 2013-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8586538B2 (en) | Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII | |
JP6527918B2 (en) | Factor VIII composition, and method and use of making the composition | |
JP6336522B2 (en) | Factor VIII mutant with reduced cellular uptake | |
US20220213200A1 (en) | Anti-gpiib/iiia antibodies or uses thereof | |
KR101841870B1 (en) | Targeted coagulation factors and method of using the same | |
TWI573806B (en) | Biologically active peptides | |
US7615622B2 (en) | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII | |
CA2349468C (en) | Factor viii polypeptide having factor viii:c activity | |
AU626255B2 (en) | Factor viii binding domain of von willebrand factor | |
WO2005047322A2 (en) | Factor viii compositions and methods | |
US20220089685A1 (en) | Red blood cell targeted factor viii and method of using the same | |
US20210355231A1 (en) | Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr) | |
JP2019511457A (en) | Anti-VWF D'D3 single domain antibody and polypeptide comprising the same | |
EP3065769A1 (en) | Procoagulant fusion compound | |
Chavin et al. | The Purification, Structure, and Function of Factor VIII | |
WO2018037217A1 (en) | Clotting factor | |
WO2001058475A1 (en) | Regulation of platelet adhesion and aggregation | |
US20030040515A1 (en) | Regulation of platelet adhesion and aggregation | |
Schaub | Inhibitors of Platelet Adhesion: VWF-GP1b/IX and Collagen-GPVI Inhibitors | |
FVIII | A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003725109 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2484155 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003227687 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004501452 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003725109 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10512907 Country of ref document: US |